HC Wainwright Reiterates Buy Rating for Compass Therapeutics (NASDAQ:CMPX)

by · The Cerbat Gem

HC Wainwright reissued their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a research note published on Monday morning,Benzinga reports. The firm currently has a $10.00 price target on the stock.

CMPX has been the subject of several other reports. Wedbush reiterated an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, August 7th. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Monday, September 16th.

View Our Latest Analysis on Compass Therapeutics

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $1.69 on Monday. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34. The company’s 50-day simple moving average is $1.75 and its 200 day simple moving average is $1.41.

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. On average, equities research analysts forecast that Compass Therapeutics will post -0.42 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Bleakley Financial Group LLC acquired a new stake in shares of Compass Therapeutics in the first quarter valued at $80,000. Renaissance Technologies LLC increased its position in Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after acquiring an additional 70,200 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Compass Therapeutics by 10.3% in the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after acquiring an additional 12,315 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Compass Therapeutics by 1.7% during the first quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after purchasing an additional 71,008 shares in the last quarter. Finally, Panagora Asset Management Inc. bought a new stake in shares of Compass Therapeutics during the second quarter valued at approximately $68,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

(Get Free Report)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

See Also